Anzeige
Mehr »
Montag, 16.03.2026 - Börsentäglich über 12.000 News
Startschuss in Nevada: Dieser Kupfer-Explorer könnte vom US-Rohstoffboom profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41HQ7 | ISIN: US80512Q5018 | Ticker-Symbol: 80W
NASDAQ
16.03.26 | 16:53
0,813 US-Dollar
-6,67 % -0,058
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXENTIS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
NEXENTIS TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur NEXENTIS TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrNexentis Launches Corporate Website1
FrNexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform1
25.02.N2OFF, Inc. - 8-K, Current Report-
25.02.N2OFF Inc.: N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company634New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve...
► Artikel lesen
NEXENTIS TECHNOLOGIES Aktie jetzt für 0€ handeln
20.02.Plantify Foods Inc (2): Plantify holder N2OFF's shareholdings decrease to 14.6%2
19.02.Plantify Foods, Inc.: N2OFF, Inc. Provides Early Warning Disclosure3
12.02.N2OFF Inc.: MitoCareX Bio Reports Successful Results in Vitro: MITOLINE-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases137MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
02.02.N2OFF Inc.: In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions1
22.01.N2OFF Inc.: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform176MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases - A Market Projected to Exceed $120 billion by 2030 Neve...
► Artikel lesen
15.01.N2OFF Inc.: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions2
12.01.N2OFF vergütet Berater für Investor Relations mit 35.000 Aktien2
12.01.N2OFF, Inc. - 8-K, Current Report-
05.01.N2OFF treibt europäisches Solarportfolio mit Meilenstein bei deutschem Projekt voran3
05.01.N2OFF advances European solar portfolio with key German project milestone2
05.01.N2OFF Inc.: N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake2
29.12.25N2OFF advances European solar portfolio with key milestones in Germany, Italy1
29.12.25N2OFF Inc.: N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy473Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build)...
► Artikel lesen
16.12.25N2OFF, Inc. - 8-K, Current Report-
18.11.25N2OFF Inc.: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination243Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following...
► Artikel lesen
13.11.25N2OFF, Inc. - 10-Q, Quarterly Report-
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1